Molecular Partners AG (MOLN)

NASDAQ · Health care · Biological Products, (No Diagnostic Substances) · Financial statements, TTM figures and earnings dates

In fiscal year 2025 (ended December 31, 2025), Molecular Partners AG reported revenue of CHF 0 and net income of −CHF 61.7M. Annual financial statements are available for fiscal years 2019 to 2025, taken from the company's filings with the SEC.

Open interactive financials →

Key financials

CHF	FY2025 2025-12-31	FY2024 2024-12-31	FY2023 2023-12-31	FY2022 2022-12-31	FY2021 2021-12-31
Income statement
Revenue	CHF 0	CHF 5.0M	CHF 7.0M	CHF 189.6M	CHF 9.8M
Operating income	−CHF 58.1M	−CHF 61.2M	−CHF 61.1M	CHF 116.6M	−CHF 63.4M
Net income	−CHF 61.7M	−CHF 54.0M	−CHF 62.0M	CHF 117.9M	−CHF 63.8M
Diluted EPS	−CHF 1.65	−CHF 1.59	−CHF 1.89	CHF 3.54	−CHF 2.06
Cash flow
Operating cash flow	−CHF 51.3M	−CHF 59.2M	−CHF 59.0M	CHF 118.6M	−CHF 91.0M
Capital expenditure	CHF 714.0K	CHF 705.0K	CHF 575.0K	CHF 1.2M	CHF 933.0K
Free cash flow	−CHF 52.0M	−CHF 60.0M	−CHF 59.6M	CHF 117.4M	−CHF 91.9M
Balance sheet
Cash and equivalents	CHF 82.7M	CHF 63.9M	CHF 67.3M	CHF 87.9M	CHF 71.8M
Total assets	CHF 102.1M	CHF 158.5M	CHF 198.4M	CHF 262.3M	CHF 172.7M
Total liabilities	CHF 21.8M	CHF 16.9M	CHF 21.9M	CHF 27.1M	CHF 65.4M
Shareholders' equity	CHF 80.3M	CHF 141.6M	CHF 176.4M	CHF 235.2M	CHF 107.3M

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in CHF as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full MOLN page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open MOLN financials →